tbuckley/cabot-search huggingface dataset:
Indication of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) in the treatment of non-seminomatous germ-cell tumors of the testis (NSGCTT): the case of minimal initial and residual disease
Authors: E. Tavernier, A. Fléchon, P. Méeus, M. Rivoire, J.-P. Droz
Journal: Journal of Clinical Oncology (2004)

4599 Background: Standard practice and indications of post-chemotherapy (CT) RPLND are based on the knowledge of retroperitoneal lymph-nodes (LN) extension (Donohue, J Urol 1982; 128: 315) and LN initial size and post-CT shrinckage (Toner, J Clin Oncol 1990; 8 : 1683). The justification of post-CT RPLND is to remove either residual cancer or teratoma (RCT) which are likely to eventually progress. The aim of the study was to delineate possible situations where RPLND could be omitted. Methods: Clinical, operative, histological charts of 153 advanced stage NSGCTT patients (pts) who had RPLND between 01/93 and 12/00 were retrospectively reviewed. Extension and size of initialy involved LN as well as size and histological patterns of LN at post-CT RPLND were studied. Results: The major predictive factor of RCT was the initial LN size : 17/41 and 74/112 pts had RCT when initial LN size was < and ≥ 30 mm respectively (p = 0.006). Pts with initial LN size < 30 mm and only one initialy involved anatomical area had still post-CT RCT in 10/21 cases. Pts with post-CT LN size less than 20 and 10 mm had RCT in 21/57 and 6/10 cases respectively. Conclusions: Presence of RCT is roughly 40–50 % of cases even in minimal initial or post-CT disease. These findings justify the indication of RPLND in case of any detectable residual disease. No significant financial relationships to disclose.
P1.03-084 Implications of 8th Edition TNM Proposal: Invasive vs. Total Size for T Descriptor in pT1a-2bN0M0 Lung Adenocarcinoma
Authors: Takashi Eguchi, Koji Kameda, Shaohua Lu, Zachary Tano, James Huang, David Jones, Prasad Adusumilli, William Travis
Journal: Journal of Thoracic Oncology (2017)
The Changing Role of Whole-Brain Radiotherapy
Authors: Minesh P. Mehta, Hidefumi Aoyama, Vinai Gondi
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P287 Patient preference for inhalation devices in copd: a comparison of the breezhaler and respimat devices
Authors: P O’Hagan, J Dederichs, V Boomi, M Gasser, S Walda
Journal: Thorax (2016)

<h3>Background and aims</h3> Difficulties and errors in the use of maintenance inhalation devices in COPD are common and can result in loss of control and an increased risk of exacerbations, hospitalisation and death. In this research, participants handled the Breezhaler® (BH) device (Novartis) and the Respimat® (RM) device (Boehringer Ingelheim) assessing each against a number of handling-related device attributes and against each other, to reveal their preferred device. <h3>Method</h3> 240 maintenance device-naive respondents across Australia, Brazil, Germany and Japan handled each device in a randomised order. Prior to handling the devices, participants ranked 22 handling-related device attributes according to their perception of importance for use. Participants familiarised themselves with the correct handling procedure for each device by consulting relevant ‘Instructions for Use’ and short training videos. After device-handling, participants indicated their level of agreement with pre-defined handling attributes on a 7-point scale from ‘I do not agree at all’ to ‘I completely agree’. In addition and after having handled both devices, participants expressed their preference for one device over the other by splitting 100 points between them. <h3>Results</h3> Participants perceived BH to be superior to RM on 20 of 22 and similar on 2 of 22 handling-related device attributes (Figure 1). Participants found BH more intuitive to use (69:31), easier to use (60: 40) and offering higher confidence that the full dose has been taken (58:42). Finally, there was a preference for BH over RM (56:44). <h3>Conclusions</h3> The consistently higher preference for BH regarding device handling-related attributes and its position as the preferred device suggest that it offers an opportunity for improved compliance and therefore improved control of COPD.
P1.02-072 Comprehensive Genomic Alterations Identified by Next-Generation Sequencing of Lung Adenocarcinoma in Japanese Population
Authors: Seijiro Sato, Masayuki Nagahashi, Tatsuya Goto, Akihiko Kitahara, Terumoto Koike, Kazuki Takada, Tatsuro Okamoto, Keisuke Kodama, Hiroshi Izutsu, Mitsutaka Nakada, Yoshihiko Maehara, Toshifumi Wakai, Masanori Tsuchida
Journal: Journal of Thoracic Oncology (2017)
Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma
Authors: Salomon Manier, Antonio Sacco, Patricia Maiso, Yong Zhang, Yang Liu, Yosra Aljawai, Weixin Wang, Meghan Corrigan-Cummins, Xavier Leleu, Katherine R. Calvo, Ola Landgren, Aldo M. Roccaro, Irene Ghobrial
Journal: Blood (2012)
Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.
Authors: Petra Muus, Jeffrey Szer, Hubert Schrezenmeier, Robert A Brodsky, Monica Bessler, Gérard Socié, Alvaro Urbano-Ispizua, Jaroslaw P Maciejewski, Wendell F Rosse, Yuzuru Kanakura, Gus Khursigara, Anders Karnell, Camille L Bedrosian, Peter Hillmen
Journal: Blood (2010)
Low back pain and sciatica: summary of NICE guidance
Authors: Ian A Bernstein, Qudsia Malik, Serena Carville, Stephen Ward
Journal: BMJ (2017)

#### What you need to know

Low back pain is the leading cause of long term disability worldwide.1 The lifetime incidence of low back pain is 58-84%,2 and 11% of men and 16% of women have chronic low back pain.3 Back pain accounts for 7% of GP consultations and results in the loss of 4.1 million working days a year.2 More than 30% of people still have clinically significant symptoms after a year after onset of sciatica.4

This guideline replaces the National Institute for Health and Care Excellence (NICE) guideline on early management of low back pain in adults (2009) and expands its remit. It summarises the updated recommendations from NICE for the assessment and management of low back pain and sciatica.5 For a visual summary, please see infographic. It is intended to overcome patchy commissioning of back pain pathways and pain management programmes6 and poor implementation due to clinicians’ beliefs that previous recommendations were constraining clinical practice.7

NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence …
Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative.
Authors: Andrea Ferrario, Lilla Cro, Nadia Zucal, Marta Lionetti, Francesco Bertoni, Lucia Nobili, Sonia Fabris, Katia Todoerti, Fortunato Morabito, Giovanna Cutrona, Agostino Cortelezzi, Andrea Guffanti, Maria Cecilia Goldaniga, Stefano Luminari, Luigi Marcheselli, Manlio Ferrarini, Antonino Neri, Giorgio Lambertenghi Deliliers, Luca Baldini
Journal: Blood (2009)
Chemotherapeutic drugs–induced apoptosis-related mRNAs in whole blood ex vivo as a new diagnostic markers for the prediction of clinical outcome of AML.
Authors: N. Usui, K. Mitani, T. Maeda, T. Sakura, N. Dobashi, F. Yagasaki, K. Obata, M. Mitsubashi, S. Miyawaki
Journal: Journal of Clinical Oncology (2011)

6627 Background: The probability of complete remission (CR) of acute myeloid leukemia (AML) is around 60 to 80%. Although age of patients and cytogenetic characteristics of leukemic blasts are known to be associated with clinical outcome, no “drug sensitivity test” is currently available to predict and tailor individualized medicine. Methods: Heparinized whole blood was drawn from AML patients before induction therapy. Blood was stored at 4°C overnight, then triplicate aliquots of 0.07mL each of blood was stimulated with cytarabine (AraC), daunorubicin (DNR), idarubicin (IDR), mitoxantrone (MIT), aclarubicin (ACR), etoposide (VP16), or solvent control for 4 hours (total 39 mRNA preparations/patient). Control genes (beta-actin (ACTB), CD4), cytostatic marker CDKN1A, and proapoptotic marker BBC3 mRNAs were quantified by real time polymerase chain reaction (PCR). The results of mRNA analysis were compared with each patient’s clinical outcome. Results: 66 subjects were enrolled, 29 were evaluable. Median age was 48 years old (25-64) with male:female ratio of 15:14. The CR rate was 69% (20 subjects). Although each drug-induced mRNA result was not correlated with CR, multivariative discrimination analysis with all mRNA data combined demonstrated 95.0% sensitivity and 88.9% specificity for the prediction of CR and non-CR. Conclusions: Measurement of chemotherapeutic drugs-induced CDKN1A and BBC3 mRNA expression in whole blood ex vivo was capable of predicting clinical outcome of induction therapy on AML. This study will be a foundation for subsequent prospective clinical studies.
P1.05-013 Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer
Authors: Ester Munera Maravilla, Alejandro Herreros Pomares, Silvia Calabuig Fariñas, Eva Escorihuela, Elena Duréndez, Aminta Isabel Martinez, Miguel Martorell, Ana Blasco, Eloisa Jantus-Lewintre, Carlos Camps
Journal: Journal of Thoracic Oncology (2017)
Abstract 338: Neuronal Responses to Hypoxic Stress in Mouse Cognitive Cortex
Authors: Guanghong Ding, Ruqing Liu, Dongman Chao, Ying Xia
Journal: Circulation Research (2012)

Cardiovascular disorders may cause hypoxic/ischemic injury to the cortex, leading to dysfunction of cortical cognition with a worse outcome in the older population. Although damage to cognitive cortex has been implicated in cognitive dysfunctions, the exact pathophysiology of a hypoxic/ischemic insult to this region is not well understood yet at the cellular and molecular levels. We used the whole-cell patch clamp in mouse slice preparations to characterize the basic electrophysiological properties of pyramidal cells of prefrontal cortex (PFC) and determine the response of these neurons to hypoxic stress in young adult (24±4 days old, n=7) and relatively older (42±12 days old, n=17) mice. In relatively older adult neurons (42±12 days old, n=17), the currents evoked by stepping from -140 mV to 20 mV (IV, holding at -60 mV) were shifted upward by hypoxic stress, indicating an increase in membrane conductance. Whole cell currents (holding at -60 mV) were found to decrease with a 3-min hypoxia, while increased with 5-min and 7-min hypoxia, suggesting that prolonged hypoxia increased open probability of ion channels. Resting membrane potential (MP) shifted upward in all three hypoxic conditions with a larger change seen with the longer duration of hypoxia. Action potentials (APs) showed the same tendency with 7-min hypoxia, showing a significant reduction in the number of hypoxia-stimulated pulses. However, all hypoxic conditions blocked the APs generation, suggesting hypoxic inhibition of neuronal excitability. In contrast, hypoxia-induced IV was apparently reversed in the younger neurons as compared to the older neurons, especially after 5 minutes of hypoxia (99.26 pA vs. -14.91 pA at -100 mV, P&lt;0.01). Interestingly, even in normoxic condition, MP was significantly larger in young adult neurons (-74.38 mV) than in the older ones (-64.67 mV) (P&lt;0.001). These data suggest that younger pyramidal cells of PFC are less vulnerable to hypoxic stress. Moreover, our preliminary data showed that activation of the delta-opioid receptors (DOR) inhibited the hypoxic response in the older neurons. Since acupuncture induces DOR up-regulation in the cortex, it is likely that acupuncture protects cortical neurons against hypoxic/ischemic stress via the DOR mechanism.
Identifying Small Molecules That Overcome HoxA9-Mediated Differentiation Arrest in Acute Myeloid Leukemia
Authors: David B. Sykes, Mark K Haynes, Nicola Tolliday, Anna Waller, Julien M Cobert, Brian A. Szekely, Tom P. Hasaka, Larry Sklar, Leonard I. Zon, David T. Scadden
Journal: Blood (2012)
Improving the Sensitivity and the Specificity of HLA-B27 Typing by Replacing Serological Tests with a TaqMan-PCR Assay
Authors: Xiaoduan Weng, Louise Robin, Marie-lise Audet, Linda Hébert, Ginette Lapointe, Micheline Major, Bernard Lemieux, Guy Biron, Karl Bélanger, Denis Soulières
Journal: Blood (2008)
P113 Indeterminate IGRA results prior to anti-tnf therapy: stable state testing may be important for immune-mediated inflammatory disorders
Authors: W Ibrahim, Y Abunga, J Mamo, S Beck, SO Brij
Journal: Thorax (2016)

<h3>Introduction</h3> Screening for active tuberculosis (TB) and latent TB infection (LTBI) is mandatory prior to the initiation of anti-TNF therapy in patients with immune-mediated inflammatory diseases (IMID). In 2010, our local guideline included QuantiFERON®-TB Gold (QFT) as well as clinical risk stratification. However, indeterminate QFT results were increasingly identified in this population, higher than that observed in other published series. <h3>Aims</h3> To identify patient and IMID characteristics that may be contributing to inderterminate QFT results and LTBI diagnostic uncertainty. <h3>Methods</h3> We conducted a retrospective study of all patients that had received at least one dose of anti-TNF since 2010. Data obtained included patient demographics, TB risk stratification and QFT results. <h3>Results</h3> 181 patients (M:F 87:94; age range 11–83; average age 44.8 years) had received at least one dose anti-TNF and were included in this study (see Table). The majority of patients had colitis (n = 143; 79%). 52 patients (28.7%) did not have a documented QFT or IGRA (interferon gamma release assay) result. LTBI was diagnosed in 8 (6.2%) with reactive QFT of whom 7 completed chemoprophylaxis and 1 was referred for further investigation and treatment elsewhere. 95 (73.6%) were QFT non-reactive. 26 (20.2%) were QFT indeterminate, all of whom had a diagnosis of colitis. Colitis patients were more likely to be QFT indeterminate if they were tested at the time of rescue anti-TNF with or without surgery (RR 5.71; 95% CI: 2.49–13.09; p &lt; 0.0001). 2 patients who received rescue anti-TNF and were subsequently found to be QFT reactive, successfully completed LTBI chemoprophylaxis. <h3>Conclusion</h3> The rate of indeterminate QFT results is higher than expected in our cohort of patients with colitis who require rescue anti-TNF therapy and is likely to be related to the timing of testing. If QFT testing is undertaken, this should be performed when patients are at stable state and not at the time of inflammatory crisis.
Medical Jurisprudence, Forensic Medicine and Toxicology.
Authors: Frank S. Green
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.07-027 13-Gene Signature of EMT Reveals Impact on Invasion and Metastasis of Neuroendocrine Carcinomas of the Lung: A Preliminary Study
Authors: Tabatha Prieto, Vanessa De Sá, Eloisa Olivieri, Eduardo Da Silva, Rui Reis, Dirce Carraro, Vera Capelozzi
Journal: Journal of Thoracic Oncology (2017)
Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure Thalassemia Major Population,
Authors: Vitrano Angela, Rita Barone, Gaetano Restivo Pantalone, Paolo Rigano, Marcello Capra, Liana Cuccia, Francesco Gagiardotto, Lorella Pitrolo, Luciano Prossomariti, Aldo Filosa, Maria Antonietta Romeo, Vincenzo Caruso, Crocetta Argento, Calogera Gerardi, Saveria Campisi, Pietro Violi, Paolo Cianciulli, Michele Rizzo, Giuseppe D'Ascola, Alessandra Quota, Carmelo Fidone, Gaetano Roccamo, Antonella Carollo, Luciana Rigoli, Francesca Valeria Commendatore, Roberto Giugno, Grazia Colletta, Rocca Cingari, Maria Concetta Galati, Antonella Quarta, Aurelio Maggio
Journal: Blood (2011)
P3.02c-101 Immunotherapy with Nivolumab in NSCLC Patients: One Centre Preliminary Results
Authors: Sofia Lampaki, Efimia Boutsikou, Paul Zarogoulidis, Dionisios Spyratos, Ellada Eleptheriadou, Despoina Ioannidou, Christoforos Efthimiou, Theodoros Kontakiotis, Konstantinos Zarogoulidis
Journal: Journal of Thoracic Oncology (2017)
P236 The role of histone arginine methylation in gene expression of airway smooth muscle cells in asthma
Authors: KA Kaczmarek, RL Clifford, JK Patel, DE Shaw, J Dowden, AJ Knox
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Asthma is estimated to affect at least 300 million people globally. About 25% of the patients do not respond to therapy; therefore we need to develop novel treatments. ASM cells have a crucial role in asthma, contributing to airway remodelling, inflammation and airflow obstruction. We have previously shown that epigenetic histone modifications, particularly histone lysine acetylation and methylation regulate the secretion of inflammatory mediators from ASM cells. Here we tested the hypothesis that histone arginine changes are also involved. Protein arginine N-methyltransferases (PRMTs) are the enzymes which catalyse histone arginine methylation (HRme, the addition of a methyl group to arginine residues on the N-terminal tails of histones), and inhibiting them represents a strategy to reduce the secretion of inflammatory mediators from ASM cells. <h3>Methods</h3> Studies were performed in cultured human ASM cells from asthmatic and non-asthmatic donors at passage 6. PRMT expression in human ASM cells was investigated by qPCR. Protein levels of four PRMTs in human ASM cells were investigated by western blotting. As PMRT1 has previously been suggested to play a role in mouse asthma models, we studied the association of PRMT1 with eotaxin, IL-6, IP-10 and CXCL8 promoters in healthy ASM cells, under basal conditions and following stimulation with TNF-α (1ng/ml), by chromatin immunoprecipitation (ChIP). IgG was used as a negative control, while acetylated histone H4 (AcH4) was used as a positive control. <h3>Results</h3> We found that ASM cells express the PRMT1, PRMT2, PRMT3, CARM1, PRMT5, PRMT6, PRMT7 and FBX011 mRNA and PRMT1, CARM1, PRMT5, and PRMT6 protein. The analysis showed no difference in the levels of expression between cells isolated from asthmatic and non-asthmatic donors. Under basal conditions, PRMT1 was associated with all of the promoters and association increased following 1 hour stimulation with TNF-α. <h3>Conclusions</h3> ASM cells express a number of PRMTs at mRNA and protein levels. PRMT1 associates with a number of chemokine and cytokine promoters after TNF-α stimulation. PRMTs may have an important role in regulating chemokine production from ASM cells in asthma, and are a promising target for future investigations in asthma.
Validation of the NIH Criteria of the Severity Grading of Chronic Gvhd – Results of a Prospective German Multicenter Validation Trial.
Authors: Daniel Wolff, Philipp Herzberg, Pia Heussner, Friederike Mumm, Inken Hilgendorf, Stephanie von Harsdorf, Philipp Hemmati, Armin Gerbitz, Michael Schmitt, Ernst Holler, Hildegard Greinix
Journal: Blood (2009)
Sugar coating bronchiectasis
Authors: Michael Loebinger
Journal: Thorax (2017)

Bronchiectasis is a condition characterised by damage and dilatation of airways. Clinically, this manifests with productive cough and recurrent infective exacerbations. The importance of bronchiectasis is increasingly becoming recognised with data demonstrating an increased prevalence and significant associated morbidity, mortality and healthcare burden.1 ,2 This has stimulated a surge in interest from academics and industry alike, with the start of several multicentre clinical trials. These have however been limited in part by the heterogeneity of bronchiectasis, with multiple different causes and significant variability in disease progression.3 The development of bronchiectasis severity scoring systems4 has helped to stratify patients into prognostic groups; however, the underlying basis for much of this heterogeneity has not been determined.

In Thorax , Taylor et al 5 investigate one possible genetic predisposition to a worse bronchiectasis phenotype. They used the well-published, prospective cohort from the BLESS trial, which assessed the impact of long-term erythromycin on exacerbation rate.6 They focus their attention on the ability of the 112 patients to secrete histo-blood group antigens which is known to be a genetically determined autosomal trait encoded by the FUT2 gene.7 This gene encodes fucosyltransferases, which act to attach fucose to disaccharide precursors and hence control the expression of ABO antigens on the epithelial mucin glycans (‘secretors’). Approximately 25% of the population are known to be homozygous for nonsense mutations in the FUT2 gene which results in an inability to produce antigens on the epithelial surface and an absence of ABO antigens on secreted mucins, providing a different mucin glycan phenotype (‘non-secretors’).7 ,8 Microbes may use these carbohydrates for adherence, invasion, induction of virulence genes and as sources of carbon.8 Differences in such glycosylation between secretors and non-secretors may therefore impact the host–pathogen interaction, and previous studies have demonstrated that …
Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-κB Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS).
Authors: Yue Wei, Rui Chen, Carlos E. Bueso-Ramos, Hui Wang, Xingzhi Song, Jing Wang, Hui Yao, Martin Nguyen, Michael Fernandez, Hui Yang, Guillermo Garcia-Manero
Journal: Blood (2009)
P2.06-004 A Phase 1b Study of Erlotinib and Momelotinib for EGFR TKI Naïve EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Authors: Sukhmani Padda, Karen Reckamp, Marianna Koczywas, Joel Neal, Carrie Brachmann, Jun Kawashima, Shengchun Kong, Yan Xin, Daniel Huang, Heather Wakelee
Journal: Journal of Thoracic Oncology (2017)